Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature

摘要: Abstract Background Patients diagnosed with advanced non-small cell lung cancer have a dismal prognosis and are often relative resistant to chemotherapy. A need for markers has emerged based on tumour biology in order predict which patients will respond treatment. Excision repair cross-complementation group 1 (ERCC1) shown potential as predictive marker NSCLC treated cisplatin-based Carboplatin gained widespread use the treatment of its mechanisms action likely similar that cisplatin. Materials methods literature review ERCC1 was conducted predictor receiving platinum-based emphasis carboplatin. English language publications from January 1996 February 2008 were eligible data methodology outcome recorded. Results Eight preclinical articles, 25 clinical articles abstract identified. Laboratory mainly RT-PCR (reverse transcriptase polymerase chain reaction) or immunohistochemistry (IHC) expression ERCC1. Preclinical studies pointed towards chemotherapy-resistance among platinum compounds. statistically significant benefit found patients, who received adjuvant treatment, had low-ERCC1 expression. Advanced cisplatin showed improved response rates (RR) but no difference other endpoints. Studies carboplatin sparse, heterogeneous small thus reporting varying results. Conclusion The dominated by patient populations yielded different No firm conclusions can be drawn current literature. Research development reliable is warranted followed validation large, prospective, randomized trials may possibly play an important role tailored chemotherapy NSCLC.